Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

AACR 2023 | Novel biomarkers of response to ICI in melanoma

Jeffrey Weber, MD, PhD, NYU Langone Medical Center, New York, NY, comments on the role of an ectoenzyme-expressing T cell population in immune checkpoint inhibitor (ICI) efficacy in patients with melanoma. These CD38+CD39+ T cells have found to have an immunosuppressive effect, and have additionally been identified as potential targets to enhance immune checkpoint blockade in patients. This interview took place at the American Association for Cancer Research (AACR) Annual Meeting 2023 in Orlando, FL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.